

LISTA DE LUCRĂRI

1. Teza de doctorat

T1. „Tulburari psihice in Scleroza multipla”, Universitatea Oradea, Facultatea de Medicina si Farmacie. Îndrumător - prof. univ. dr. Petru Mihancea.

2. Publicatii

A. Cărți publicate, îndrumare/culegeri publicate

A1. Horia Ardelean, **Claudiu Sorin Iova**, Gheorghe Oros, „*Psihiatrie pentru Colegiul de asistenti medicali*” Editura Universitatii din Oradea, 2006, ISBN (10)973-759-217-4, ISBN (13)978-973-759-217-0, curs 228pg.

B. Capitole publicate în volume colective

3. Articole/studii publicate

A. In reviste de specialitate de circulație internațională recunoscute cotate ISI sau indexate în baze de date internaționale specifice domeniului, care fac un proces de selecție a revistelor pe baza unor criterii de performanta

A1. Paina Gh., Ardelean H., Belba Adriana, **Claudiu Sorin Iova**, „*The social phobia – clinical, epidemiological and therapy considerations*” ; Archives of the Balkan Medical Union; vol39, nr3 ,sept.2004, pg 259-260. Celsius Publishing House ISSN 0041-6940 cota BDI

A2. **Claudiu Sorin Iova**, Popescu Codruța Alina, Claudia Andrada Iova, Petru Mihancea, Buzoianu Anca Dana, *Impact of depression on coping strategies in multiple sclerosis patients*, vol 6(4)/2014 of the scientific/academic journal: Human & Veterinary Medicine – International Journal of the Bioflux Society, Bioflux (publishing house) 54 Ceahlau Street, Cluj-Napoca 400488, Romania, European Union

A3. **Claudiu Sorin Iova**, Popescu Codruța Alina, Claudia Andrada Iova, Petru Mihancea, Buzoianu Anca Dana, *Personality traits in multiple sclerosis: association with mood and anxiety disorders in a Romanian patients sample*, vol 6(4)/2014 of the scientific/academic journal: Human & Veterinary Medicine – International Journal of the Bioflux Society, Bioflux (publishing house) 54 Ceahlau Street, Cluj-Napoca 400488, Romania, European Union

A4. Andrada Iova, Otilia Micle, Laura Vicas, Liana Micle, **Sorin Iova**, Mariana Muresan, Corina Ana Ionita – „*Oxidative stress in Alzheimer's Dementia*”, revista Farmacia, vol 62.3/2014, ISSN: 0014-8237 (for the Printed Edition) ISSN: 2065-0019 (for the On-Line Edition)

A5 Rareș Oros, Popescu Codruța Alina, Claudia Andrada Iova, **Claudiu Sorin Iova**, Petru Mihancea “*The Impact of cognitive impairment after stroke on activities of daily living*” vol 8/issue 1/2015 of the scientific/academic journal: Human & Veterinary Medicine – International Journal of the Bioflux Society, Bioflux (publishing house) 54 Ceahlau Street, Cluj-Napoca 400488, Romania, European Union

A6 . Rareș Oros, Popescu Codruța Alina, Claudia Andrada Iova, **Claudiu Sorin Iova**, Petru Mihancea „*Depression, activities of daily living and quality of life in elderly stroke patients*”, vol 8/issue 1/2015 of the scientific/academic journal: Human & Veterinary Medicine – International Journal of the Bioflux Society, Bioflux (publishing house) 54 Ceahlau Street, Cluj-Napoca 400488, Romania, European Union

B. Indexate în baze de date internaționale recunoscute (BDI)

C. In alte reviste de specialitate de circulație internațională

D. In reviste din țară recunoscute C.N.C.S.I.S.

E. In alte reviste de specialitate de circulație națională cu (ISBN, ISSN)

F. Citări ISI/BDI/Alte reviste

4. Articole/studii publicate

A. In volumele unor manifestări științifice: (se precizeaza daca este cazul -cotate ISI sau indexate în baze de date internaționale-BDI)

- A1. **Sorin Iova**, Georgeta Pasca, Andrada Iova, Adrian Bumbu, Lavinia Purza „Life Stress Factors and General Anxiety Disorder”, International Symposia of Risk Factors for Environment and Food Safety & Natural Resources and Sustainable Development, University of Oradea, Faculty of Environmental Protection, 6-7 nov. 2015, Oradea
- A2. Georgeta Pasca, Sorin Iova, Andrada Iova, Adrian Bumbu, Lavinia Purza „Seasonal Variation of Major Depressive Disorder” ”, International Symposia of Risk Factors for Environment and Food Safety & Natural Resources and Sustainable Development, University of Oradea, Faculty of Environmental Protection, 6-7 nov. 2015, Oradea
- A3. **Sorin Iova**, Renata Szabo, Andrada Iova, Georgeta Pasca „Agresivitatea la pacientii expertizati in comisia medico legala psihiatrica”, Al III-lea Congres Dedicat Cercetarii Stiintifice Psihiatrice Romanesti 6-8 Iunie 2013, Oradea
- A4. Adriana Belba, **CS Iova**, Anamaria Oanea „*Acidum Valproicum in tratamentul Psihozei maniaco-depressive cu cicluri rapide*” Zilele Medicale Oradene, Facultatea de Medicina si Farmacie Oradea, 25-27 nov. 2011
- A5. Ardelean H., Vladut V., Paina Gh., **Iova Claudiu Sorin**, „*The Tatoo from myth to trendiness*” 8th European ISSPD Congress, Targu-Mures, 10-13 sep 2008, ISBN 978-973-169-100-8, 159.923(063) pg.40-41
- A6. Paina Gh., Ardelean H., Vladut V., **Iova C. S.**, Sabau Teodora, „*Evaluarea tentativelor de suicid in serviciul de urgenta barbati la nivelul Spitalului Clinic de Neurologie si Psihiatrie Oradea*” , Strategii de abordare ale afectiunilor psihiatrice, Conferinta Nationala Cluj Napoca 13-16 sep 2007, pg.57
- A7. Oros Gh., **Iova Claudiu Sorin**, Iova Claudia Andrada, „*Rugaciunea, terapie nemedicamentoasa in bolile psihice*”, Conferinta Nationala a Medicilor Crestini, Valea Draganului, sep. 2004

B. Internaționale recunoscute (cu ISSN sau ISBN) țară și din străinătate

C. Naționale

5 Brevete de invenție

6 Proiecte/contracte/granturi de cercetare-dezvoltare-inovare:

A. Obținute prin competiție pe bază de contract/grant internaționale

- A1. A double-blind, positive comparator, randomized, multicenter, parallel group, study to assess the efficacy, safety and tolerability of AZD3480 (TC-1734-226) as monotherapy in patients with Mild to Moderate Alzheimer's Dementia, Protocol TC-1734-226-CRD-006, 2011-2013
- A2. A Multicenter, randomized, double-blind study to evaluate the efficacy and tolerability of an oral Aripiprazole/Escitalopram combination therapy in patients with MDD, Protocol no. 31-08-255, 31-08-256, 31-08-263, 31-08-257, 2011
- A3. A Randomized, double-blind, parallel group study of Paliperidone Palmitate evaluating time to relapse in subjects with Schizoaffective Disorder, Protocol R092670-SCA-3004, 2011
- A4. A Randomized, double-blind, phase 2/3 study to determine the short-term and long term antipsychotic and cognitive efficacy, safety and tolerability of CYP-1020 in patients with Schizophrenia, Protocol 1020-CLIN-201, 2011
- A5. A Multicenter, randomized, double-blind, parallel group, phase 3, efficacy and safety study of 3 fixed dose groups of TC-5214 as an adjunct to an antidepressant in patients with MDD who exhibit an inadequate response to antidepressant therapy, Protocol TC-5214 D4130C00005, 2011
- A6. A Randomized, double-blind, parallel-group, 24-week, adaptive design phase 2 study of three different doses of an Alpha-7 nicotinic Acetylcholine Receptor Agonist (EVP-6124) in subjects with Mild to Moderate Probable Alzheimer Dementia, Protocol EVP-6124-010, EudraCT no. 2010-018554-12, 2010-2011
- A7. A 8-week, randomised, double-blind, flexible-dose, parallel groups, international multicentre study followed by an extension double-blind treatment period of 16 weeks, following efficacy and safety of agomelatine oral administration in elderly patients suffering from Major Depressive Disorder, Protocol no. CL3-20098-070, EudraCT 2009-011795-29, 2010-2011
- A8. A 24-month, prospective, randomized, active-controlled, open-label, rater-blinded, multicenter, international study of the prevention of relapse comparing Long-Acting injectable Paliperidone Palmitate to treatment as usual with oral antipsychotic monotherapy in adults with schizophrenia, protocol no. R02670SCH3005, Eudract-no. 2008-002247-16, 2010-2012
- A9. A 52-week, multicenter, open label study to evaluate the effectiveness of Aripiprazole Intramuscular depot as maintenance treatment in patients with schizophrenia „ASPIRE OPEN-LABEL”, Protocol no. 31-08-248, Ind.no. 67380, 2010-2011
- A10. 52-week, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients with Schizophrenia. Protocol ASPIRE 33-07-246 anul 2009-2010
- A11. An Eight Week, Multicenter, Randomized, Double-Blind, Placebo-controlled Dose-Finding Study With Escitalopram as Active Control to Evaluate the Efficacy, Safety and Tolerability of 3 Fixed Doses of SSR411298 in Elderly Patients With Major Depressive Disorder, Protocol SSR411298, DFI10560, anul 2009-2010

- A12. A Phase II, 6-Week, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Oral OPC-34712 Once Daily and Aripiprazole Once Daily for Treatment of Hospitalized Adult Patients with Acute Schizophrenia, Protocol STEP 331-07-203, anul 2009-2010
- A13. A Randomized, Double-Blind, Parallel-Group, Placebo Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of a Single Dose of LUAA21004 in Acute Treatment of Adults with Generalized Anxiety Disorder, Protocol LUAA21004-311 anul 2009
- A14. A Randomized, Double-blind, Placebo and Active Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Three Fixed Doses of J&J-37822681 Administered Twice Daily in Subjects with Schizophrenia, Protocol 3782268/SCH2002 anul 2009
- A15. A Phase III Randomized, Double-blind, Placebo and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects with Schizophrenia. Protocol PEARL 3 D1050233 anul 2009
- A16. A 24-Week, Flexible-Dose, Open-Label Extension of Lurasidone for the Treatment of Bipolar I Depression, Protocol D1050256 anul 2009 - 2010
- A17. A Randomized, 6-Weeks, Double-blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression, Protocol D1050235 anul 2009
- A18. A Multi-center Depression study, Protocol 190-062, 947-010, co-investigator, 2009
- A19. A Randomised, Double-blind, Placebo-Controlled Study comparing the efficacy and safety of three dosages of LUAA21004 in acute treatment of MDD, Protocol AA21004, co-investigator, 2008
- A20. Double-Blind, Parallel-Group Comparison of 23mg Donepezil Sustained Release to 10mg Donepezil Immediate Release in Patients with Moderate to Severe Alzheimer's Disease, Protocol E2020-G000-326 and E2020-G000-328, co-investigator, 2008
- A21. A six-week, randomised, double-blind, placebo-controlled, parallel group, Phase II study to determine the efficacy, tolerability and safety of low and high non-overlapping dose ranges of BL-1020 compared to placebo and risperidone in patients with acute exacerbation of schizophrenia, Protocol BL-1020 IIb, co-investigator, 2008
- A22. A 52 weeks, Randomised, Double-blind, Study to evaluate the Long-term Efficacy, Safety and Tolerability of an Intramuscular Depot Formulation of OPC-14597 in patients with Schizophrenia, Protocol 31-07-247 and 31-07-248,
- A23. A Randomised, Double-blind, fixed-dose, 6-week trial of the efficacy and safety of Asenapine compared with placebo using haloperidol positive control in subjects with an acute exacerbation of schizophrenia, Protocol 041023 and 041513, co-investigator, 2006
- A24. A Randomised, partially-blinded, parallel-group, active-controlled study, Protocol 99824 in subjects with schizophrenia, study coordinator, 2005
- A25. A eight-week, randomised, double-blind, placebo-controlled, dose-finding study to evaluate the efficacy, safety and tolerability of three doses of SSR411298 in elderly patients with MDD, Protocol DFI10560, co-investigator, 2008
- A26. A double-blind, randomised, placebo-controlled study of the long-term Compound's efficacy, safety and tolerability in patients with chronic schizophrenia, Protocol 10214 and 10265, co-investigator, 2005
- A27. A Randomised, Double-blind, Placebo-Controlled Study comparing the efficacy and safety of Compound in subjects with an acute exacerbation of schizophrenia, Protocol SCH 301 / 701, study coordinator, 2004

B. Obținute prin competiție pe bază de contract/grant naționale

C. Contracte de cercetare cu mediul socio-economic

7. Recunoașterea prestigiului științific

A. Conducere de doctorat

B. Referent în comisii de doctorat internaționale în ultimii 5 ani

C. Membru în colective de redacție ale unor reviste științifice recunoscute

D. Referent atestat al unor reviste științifice cotate ISI sau indexate în BDI în ultimii 5 ani

E. Expert științific atestat național / internațional

F. Premii

G. Membru în asociații științifice și profesionale

G1. Membru în Colegiul medicilor Bihor

G2. Membru în asociația Medscape (www.medscape.com)

G3. Membru în Comisia de internari nevoluntare a Spitalului Clinic Municipal “dr. Gavril Curteanu” secțiile de Psihiatrie.

G4. Membru în Comisia de Expertiza medico-legală psihiatrică Oradea

8. Altele neprecizate mai sus.

Notă

(I) Fiecare lucrare este prezentată, în limba în care a fost publicată/expusă; (I) - autorii în ordinea din publicație, cu scriere “bold” a **titularului**; II – *titlul*, scris “italic”; III - editura sau revista sau manifestarea și/sau alte elemente de localizare, după caz (ISI, Baza de date de indexare, ISSN/ISBN etc.); IV - intervalul de pagini din publicație, respectiv, pp ...-..., numărul total de pagini, respectiv, ... pg., sau alte date similare, după caz; V - anul sau perioada de realizare, după caz.

(2)-la contracte se trec elementele de identificare: titlu, numărul contractului, tip/ sau finanțator (CNCSIS, FP6, etc), director/instituația, număr de parteneri, responsabil(dacă Universitatea Oradea este partener), suma totală, anul/anii de derulare a contractului;

(3) În cadrul fiecărui grup de lucrări, lucrările sunt în ordine invers cronologică.